PA
VRSN icon

PharVision Advisers’s VeriSign VRSN Stock Holding History

PharVision Advisers’s Portfolio VRSN Stock Details VRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,998
Closed -$485K – 642
2025
Q4 		$485K Buy
1,998
+1,234
+162% +$310K 0.25% 47
2025
Q3 		$214K Buy
+764
New +$213K 0.12% 460
2025
Q2 		– Sell
-823
Closed -$209K – 442
2025
Q1 		$209K Buy
+823
New +$187K 0.29% 190

Other funds holding VRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

PharVision Advisers's VRSN Position: Q1 2026 in Review

PharVision Advisers sold out of VeriSign (VRSN) in Q1 2026, closing a stake of 1,998 shares — an estimated $485K sold.

PharVision Advisers first reported a position in VRSN in Q1 2025 and held it in 3 quarters. The position peaked at $485K in Q4 2025. 852 funds tracked by Wall St. Rank hold VRSN as of Q1 2026.

  • PharVision Advisers reported no remaining VeriSign position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 1,998 VeriSign shares in Q1 2026, an estimated $485K.
  • PharVision Advisers first reported a position in VeriSign in Q1 2025 and held it in 3 quarters.
  • PharVision Advisers's VeriSign position peaked at $485K in Q4 2025.
  • 852 funds tracked by Wall St. Rank held VeriSign as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.